-
Mashup Score: 3Xilis and MD Anderson Announce Strategic Collaboration to Advance Novel Technology and Accelerate Therapeutic Development | BioSpace - 2 year(s) ago
Xilis and MD Anderson Announce Strategic Collaboration to Advance Novel Technology and Accelerate Therapeutic Development – read this article along with other careers information, tips and advice on BioSpace
Source: BioSpaceCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Embattled Clovis Oncology Files for Chapt. 11, Sells Radioligand Therapeutic to Novartis | BioSpace - 2 year(s) ago
Clovis Oncology officially files for Chapter 11 bankruptcy.
Source: BioSpaceCategories: Hem/Oncs, Latest HeadlinesTweet-
@CParkMD @OncoAlert @ASCO @AlanBryce9 @neerajaiims @PGrivasMDPhD @DrChoueiri @DrYukselUrun @urotoday Company bankrupt though.. https://t.co/ffkeeqmA1Z
-
-
Mashup Score: 0Phio Pharmaceuticals Announces Positive DMC Recommendation and Continued Enrollment of Advanced Melanoma Study Without Modification | BioSpace - 2 year(s) ago
Phio Pharmaceuticals Announces Positive DMC Recommendation and Continued Enrollment of Advanced Melanoma Study Without Modification – read this article along with other careers information, tips and advice on BioSpace
Source: BioSpaceCategories: Hem/Oncs, Latest HeadlinesTweet-
A different approach to PD-1 based treatment: reduce the ability of tumor cells to make PD-1. EARLY STUDY, single institution, but interesting inverted approach. https://t.co/ZPIVHD9IvV
-
-
Mashup Score: 0
The FDA granted Moderna’s RSV vaccine candidate Breakthrough Therapy Designation Monday.
Source: BioSpaceCategories: Infectious Disease, Latest HeadlinesTweet-
“The regulatory honor is based on the pivotal Phase III ConquerRSV trial, in which the mRNA-based vaccine, mRNA-1345, demonstrated 83.7% efficacy against RSV lower respiratory tract disease in older adults.” https://t.co/37ZpMl0T2r
-
-
Mashup Score: 0XyloCor Advances Cardiovascular Gene Therapy Space with Positive Angina Results | BioSpace - 2 year(s) ago
XyloCor Therapeutics reported positive topline results Thursday from Phase II of the Phase I/II trial of its gene therapy for refractory angina.
Source: BioSpaceCategories: Healthcare Professionals, Latest HeadlinesTweet-
#XyloCor Advances Cardiovascular #GeneTherapy Space with Positive Angina Results | BioSpace https://t.co/vaNFvNL7A6
-
-
Mashup Score: 0
BrainStorm Cell Therapeutics appoints a new co-CEO as it prepares for a January 11th Type A meeting for ALS hopeful NurOwn.
Source: BioSpaceCategories: Latest Headlines, Rare DiseaseTweet-
BrainStorm Preps for Type A NurOwn Meeting, Shakes Up C-Suite | BioSpace https://t.co/vMCM50SZKn #jobs
-
-
Mashup Score: 1
Gilead and EVOQ Therapeutics announced a partnership to develop immunotherapies for rheumatoid arthritis and lupus.
Source: BioSpaceCategories: Healthcare Professionals, Latest HeadlinesTweet-
Gilead Sciences and EVOQ Therapeutics have a new 2023 partnership to develop immunotherapies for RA & SLE - using NanoDisc technology with lymph-targeted delivery of disease-specific-antigens. Gilead has IRAK4 inhibitor, GS-5718in Phase I https://t.co/kanUXUhMSm https://t.co/ZaDH1ueWrl
-
-
Mashup Score: 1BioSpace's Top Biopharma M&A Candidates for 2023 | BioSpace - 2 year(s) ago
Mergers and acquisitions are expected to be a key theme in the pharmaceutical industry in 2023.
Source: BioSpaceCategories: Latest Headlines, Rare DiseaseTweet-
RT @BrielmaierL: @alsadvocacy @FoxNews have a look here https://t.co/fP1WYKjPAx
-
-
Mashup Score: 0
Verona Pharma’s COPD candidate hits the mark in late-stage testing.
Source: BioSpaceCategories: Healthcare Professionals, Latest HeadlinesTweet-
Verona Pharma Eyes NDA for COPD Drug Based on Positive Phase III Data | BioSpace https://t.co/S3ZtdEgT23 #jobs
-
-
Mashup Score: 0
Agenus Data at SITC 2022 Highlight Durable Responses of Botensilimab / Balstilimab Combination in Nine Different Treatment-Resistant Cancers – read this article along with other careers information, tips and advice on BioSpace
Source: BioSpaceCategories: Hem/Oncs, Latest HeadlinesTweet-
Always interesting to see how the "next-generation" of approved #cancer drugs, in this case immunotherapy / anti-CTLA4, fare against various types of cancer https://t.co/FBpXNyMrBT via @Agenus_Bio @ODayMD
-
Our newest platform will accelerate drug development & cellular therapies over current models. Read more about how Xilis_Inc and MDAndersonNews are developing the next generation of #cancer treatments..." https://t.co/OuQMvR6sxK